SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

IRLABA CEO Kristina Torfgård plans to step down in Q1 2027

IRLAB Therapeutics AB says its CEO Kristina Torfgård informed the board she wishes to step down during the first quarter of 2027.

IRLABA
SquawkNews Desk

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories

Thousands of US Flights Canceled and Delayed as Air Travel System Recovers Thousands of US flights were canceled or delayed as the air travel system slowly recovered from a shutdown. M impact | EQUITY | Nov 14, 2026, 06:37 PM UTC Lilly Phase 3 Trial Reports Average 21.4% BMI Reduction With Zepbound The SURMOUNT-ADOLESCENTS trial showed Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity. M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC Lilly Phase 2 Data Show Eloratzp Weight Loss of Up to 54.1 Pounds Phase 2 data showed average weight loss of up to 54.1 pounds (23.3%) at 48 weeks in adults with obesity and type 2 diabetes. M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC Novo Nordisk CagriSema Reduced Waist Circumference by 17.2–17.5 cm Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo. M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC Novo Nordisk CagriSema Shows Weight Loss in REDEFINE 9 Trial At 68 weeks, average weight loss was 20.7% with 1.7 mg/1.7 mg and 21.0% with 1.0 mg/1.0 mg, versus 2.0% with placebo. M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC Novo Nordisk Says CagriSema Reduced Waist Circumference Up to 17.5 cm Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo. M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC